Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 936 trials

Inhaled Levosimendan: Understanding How It Works

We are exploring how the body processes inhaled levosimendan in this early study. This research may help improve treatments for heart conditions.

Heart Failure>2 yearsSafety phase (I)CardiologyInternal Medicine

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Acute Myeloid Leukemia: JNJ-90189892 Treatment

We are testing a new medication for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms. The study aims to determine the safest dose and gather initial information on its effects.

Relapsed or Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

PBP1510 for Advanced Pancreatic Cancer

We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.

Advanced Pancreatic CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Kidney Transplant: Regulatory T Cell Therapy

We are studying the safety of using regulatory T cells in kidney transplant recipients to see if it helps the body accept the new kidney better. This may allow for less reliance on standard immunosuppressive medications.

Kidney TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Nivolumab and Entinostat for High-Risk Cancers in Kids

We are exploring a new treatment combining Nivolumab and Entinostat for children and adolescents with hard-to-treat cancers. The study aims to see if this combination can help those with specific tumor characteristics.

Relapsed or Refractory High-Risk Malignant Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPediatrics

HPV16-Related Throat Cancer: FluBHPVE6E7 Immunotherapy

We are testing a new immunotherapy for patients with HPV16-associated oropharyngeal squamous cell carcinoma. The goal is to evaluate its safety and how well it works in treating this type of cancer.

Human Papilloma Virus InfectionSafety phase (I)OncologyOtolaryngology

Fibrotic Lung Disease: Wharton's Jelly Stem Cells

We are studying the safety and effects of a stem cell treatment for people with fibrotic interstitial lung diseases. This research aims to see if it can improve lung function and quality of life.

Interstitial Lung Disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicinePulmonology

Small Cell Lung Cancer: ZL-1310 Study

We are testing different doses of ZL-1310 in patients with small cell lung cancer. The goal is to find a suitable dose and see how well the body tolerates and processes the medication.

Small Cell Lung Cancer6-12 monthsSafety phase (I)Oncology

Advanced NSCLC: MCLA-129 Treatment Study

We are evaluating a new bispecific antibody, MCLA-129, for patients with advanced non-small cell lung cancer. The study aims to assess its effectiveness and safety compared to standard treatments.

Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Lung Cancer: ABBV-400 and Budigalimab Study

We are testing a new treatment combining ABBV-400 and Budigalimab for adults with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to see how safe it is and how well it works.

Advanced Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Duchenne Muscular Dystrophy: SGT-003 Gene Therapy

We are studying a new gene therapy to see if it is safe and effective for males with Duchenne Muscular Dystrophy. The trial will assess improvements in muscle function and other health measures after a single intravenous dose.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Acute Myeloid Leukemia: SNDX-5613 with Chemotherapy

We are testing a new drug, SNDX-5613, combined with intensive chemotherapy for patients with AML who have certain genetic changes. The goal is to see if this combination improves treatment outcomes.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

B-Cell Lymphoma: TranspoCART19 T Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory B-cell lymphoma. The trial aims to evaluate the safety and effectiveness of this therapy in improving patient outcomes.

Relapsed or Refractory B-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Atopic Dermatitis: Methylprednisolone Aceponate Ointment

We are comparing a new ointment for atopic dermatitis with an existing treatment and a placebo. The goal is to see how well it reduces skin symptoms like itching and redness.

Mild to Moderate Atopic Dermatitis>2 yearsSafety phase (I)Investigational MedicinesAllergologyDermatology

OMX-0407 for Unresectable Solid Tumors

We are studying a new medication, OMX-0407, in patients with previously treated solid tumors to see how well it works and to find the safest dose. This trial will help us understand its effects on cancer response and patient quality of life.

Previously Treated Unresectable Solid Tumours>2 yearsSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Subarachnoid Hemorrhage: EDV2209 Medication Study

We are investigating the safety and tolerability of a new medication, EDV2209, for patients with bleeding in the brain. This study compares the effects of EDV2209 to a placebo to see how it may help in recovery.

Subarachnoid Hemorrhage>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurology

T-Cell Acute Lymphoblastic Leukemia: OC-1 CAR T Therapy

We are studying the safety and effectiveness of OC-1 therapy for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoma. This trial aims to understand how well the treatment works and its impact on patient survival.

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Rheumatoid Arthritis and Sjogren's Disease: Rapcabtagene Autoleucel Study

We are evaluating the safety of a new treatment for people with difficult-to-treat rheumatoid arthritis and severe Sjogren's disease. The study also looks at how the treatment works in the body.

Rheumatoid ArthritisSjogren's DiseaseSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineRheumatology